Alireza Atri, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 49 | 2024 | 8037 | 3.890 |
Why?
|
| Cholinesterase Inhibitors | 8 | 2019 | 238 | 2.380 |
Why?
|
| Dementia | 12 | 2023 | 2518 | 1.580 |
Why?
|
| Memantine | 7 | 2019 | 100 | 1.410 |
Why?
|
| Neuropsychological Tests | 10 | 2023 | 6993 | 0.990 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2019 | 449 | 0.910 |
Why?
|
| Neurodegenerative Diseases | 3 | 2023 | 1061 | 0.810 |
Why?
|
| Benzylamines | 3 | 2019 | 223 | 0.770 |
Why?
|
| Lewy Body Disease | 1 | 2023 | 229 | 0.770 |
Why?
|
| Parkinson Disease | 3 | 2023 | 2775 | 0.710 |
Why?
|
| Indans | 4 | 2018 | 96 | 0.670 |
Why?
|
| Serotonin Antagonists | 1 | 2018 | 144 | 0.600 |
Why?
|
| Cognition Disorders | 7 | 2019 | 4043 | 0.600 |
Why?
|
| Galantamine | 2 | 2018 | 32 | 0.560 |
Why?
|
| Amyloidogenic Proteins | 6 | 2023 | 152 | 0.480 |
Why?
|
| Dopamine Agents | 4 | 2019 | 189 | 0.460 |
Why?
|
| Indoles | 3 | 2019 | 1839 | 0.460 |
Why?
|
| Disclosure | 1 | 2019 | 736 | 0.440 |
Why?
|
| Nootropic Agents | 4 | 2019 | 160 | 0.440 |
Why?
|
| Cost of Illness | 2 | 2019 | 1859 | 0.420 |
Why?
|
| Caregivers | 4 | 2023 | 2094 | 0.420 |
Why?
|
| Phenylcarbamates | 1 | 2011 | 38 | 0.420 |
Why?
|
| Memory | 6 | 2016 | 2174 | 0.390 |
Why?
|
| Piperidines | 4 | 2018 | 1602 | 0.380 |
Why?
|
| Amyloid | 6 | 2023 | 795 | 0.370 |
Why?
|
| Hippocampus | 2 | 2014 | 3675 | 0.360 |
Why?
|
| Mental Recall | 1 | 2016 | 1205 | 0.360 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 977 | 0.350 |
Why?
|
| Psychotherapy | 1 | 2019 | 1643 | 0.350 |
Why?
|
| Amyloid beta-Peptides | 10 | 2023 | 3587 | 0.350 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 6489 | 0.330 |
Why?
|
| Disease Progression | 7 | 2024 | 13284 | 0.300 |
Why?
|
| Executive Function | 1 | 2016 | 1364 | 0.300 |
Why?
|
| Cognition | 6 | 2022 | 6770 | 0.300 |
Why?
|
| Brain Mapping | 7 | 2016 | 6669 | 0.290 |
Why?
|
| tau Proteins | 7 | 2024 | 1868 | 0.280 |
Why?
|
| Health Care Costs | 1 | 2019 | 3209 | 0.260 |
Why?
|
| Autopsy | 3 | 2023 | 1020 | 0.260 |
Why?
|
| Decision Making | 1 | 2019 | 3887 | 0.250 |
Why?
|
| Communication | 1 | 2019 | 3749 | 0.250 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7785 | 0.250 |
Why?
|
| Proactive Inhibition | 1 | 2004 | 3 | 0.250 |
Why?
|
| Humans | 66 | 2024 | 744343 | 0.240 |
Why?
|
| Word Association Tests | 1 | 2004 | 57 | 0.240 |
Why?
|
| Nerve Net | 2 | 2014 | 2174 | 0.240 |
Why?
|
| Cavernous Sinus Thrombosis | 1 | 2003 | 14 | 0.230 |
Why?
|
| Oxygen | 3 | 2012 | 4189 | 0.230 |
Why?
|
| Receptors, Cholinergic | 1 | 2004 | 238 | 0.220 |
Why?
|
| Cholinergic Antagonists | 1 | 2004 | 165 | 0.220 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2023 | 77 | 0.220 |
Why?
|
| Dementia, Vascular | 1 | 2023 | 128 | 0.210 |
Why?
|
| Brain | 11 | 2024 | 26385 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2023 | 35421 | 0.200 |
Why?
|
| Illness Behavior | 1 | 2019 | 22 | 0.180 |
Why?
|
| Parkinsonian Disorders | 1 | 2023 | 275 | 0.180 |
Why?
|
| Primary Health Care | 3 | 2021 | 4558 | 0.160 |
Why?
|
| Tauopathies | 1 | 2022 | 307 | 0.160 |
Why?
|
| Aged | 23 | 2024 | 163280 | 0.150 |
Why?
|
| Thyroid Nodule | 1 | 2004 | 750 | 0.150 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 2418 | 0.150 |
Why?
|
| Memory Disorders | 4 | 2023 | 1184 | 0.150 |
Why?
|
| Carotid Artery Diseases | 1 | 2003 | 882 | 0.140 |
Why?
|
| Patient Care Planning | 2 | 2019 | 921 | 0.140 |
Why?
|
| Functional Laterality | 1 | 2003 | 2290 | 0.140 |
Why?
|
| Aged, 80 and over | 12 | 2021 | 57776 | 0.140 |
Why?
|
| Data Collection | 3 | 2023 | 3341 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2023 | 1504 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2016 | 6600 | 0.130 |
Why?
|
| Headache | 1 | 2003 | 1226 | 0.130 |
Why?
|
| Amyloidosis | 1 | 2022 | 795 | 0.130 |
Why?
|
| Longitudinal Studies | 6 | 2023 | 13989 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2023 | 9959 | 0.130 |
Why?
|
| Double-Blind Method | 4 | 2019 | 12026 | 0.120 |
Why?
|
| Aging | 2 | 2012 | 8664 | 0.120 |
Why?
|
| Scopolamine | 2 | 2005 | 99 | 0.120 |
Why?
|
| Intracranial Aneurysm | 1 | 2003 | 1197 | 0.120 |
Why?
|
| Female | 28 | 2023 | 380194 | 0.120 |
Why?
|
| Cerebral Hemorrhage | 1 | 2005 | 2647 | 0.110 |
Why?
|
| Internationality | 1 | 2018 | 1003 | 0.110 |
Why?
|
| Male | 23 | 2023 | 350118 | 0.110 |
Why?
|
| Photic Stimulation | 3 | 2016 | 2025 | 0.110 |
Why?
|
| Tacrine | 1 | 2011 | 5 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2017 | 1184 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2018 | 2618 | 0.100 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 128 | 0.100 |
Why?
|
| Mental Status Schedule | 1 | 2012 | 321 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 2282 | 0.100 |
Why?
|
| Reaction Time | 2 | 2016 | 2097 | 0.100 |
Why?
|
| Limbic Encephalitis | 1 | 2011 | 34 | 0.100 |
Why?
|
| Atrophy | 3 | 2023 | 1583 | 0.100 |
Why?
|
| Neurofibrillary Tangles | 2 | 2024 | 439 | 0.090 |
Why?
|
| Middle Aged | 14 | 2019 | 213383 | 0.090 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2011 | 89 | 0.090 |
Why?
|
| Evoked Potentials | 1 | 2016 | 1056 | 0.090 |
Why?
|
| Face | 1 | 2016 | 994 | 0.090 |
Why?
|
| Prion Diseases | 1 | 2011 | 88 | 0.090 |
Why?
|
| Hashimoto Disease | 1 | 2011 | 97 | 0.090 |
Why?
|
| Accidental Falls | 1 | 2018 | 1062 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 2278 | 0.090 |
Why?
|
| Apolipoprotein E4 | 2 | 2023 | 668 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 2576 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 6038 | 0.080 |
Why?
|
| Electroencephalography | 2 | 2016 | 6150 | 0.080 |
Why?
|
| Oocytes | 1 | 1993 | 1187 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2019 | 2531 | 0.080 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 19905 | 0.080 |
Why?
|
| Life Style | 1 | 2019 | 3835 | 0.080 |
Why?
|
| Simvastatin | 1 | 2010 | 360 | 0.080 |
Why?
|
| Neurologic Examination | 1 | 2011 | 930 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8642 | 0.080 |
Why?
|
| Encephalitis | 1 | 2011 | 423 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 1344 | 0.070 |
Why?
|
| Time | 1 | 2008 | 542 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 10943 | 0.060 |
Why?
|
| Parahippocampal Gyrus | 1 | 2005 | 116 | 0.060 |
Why?
|
| Muscarinic Antagonists | 1 | 2005 | 137 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2016 | 3461 | 0.060 |
Why?
|
| Aspirin | 1 | 2016 | 3282 | 0.060 |
Why?
|
| Neurogranin | 1 | 2023 | 15 | 0.060 |
Why?
|
| Time Factors | 4 | 2021 | 40075 | 0.060 |
Why?
|
| Learning | 2 | 2023 | 1713 | 0.060 |
Why?
|
| Presenilin-2 | 1 | 2023 | 106 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 12959 | 0.060 |
Why?
|
| Suppuration | 1 | 2023 | 56 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 3068 | 0.060 |
Why?
|
| Plaque, Amyloid | 2 | 2023 | 729 | 0.060 |
Why?
|
| Positron-Emission Tomography | 3 | 2024 | 6234 | 0.050 |
Why?
|
| Electrons | 1 | 2023 | 268 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2012 | 6459 | 0.050 |
Why?
|
| Brain Diseases | 1 | 2011 | 1563 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2005 | 5985 | 0.050 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2000 | 3 | 0.050 |
Why?
|
| Olfactory Bulb | 1 | 2022 | 200 | 0.050 |
Why?
|
| Cholesterol | 1 | 2010 | 2917 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2011 | 5078 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2016 | 4599 | 0.050 |
Why?
|
| Ehrlichiosis | 1 | 2000 | 29 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3610 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 8949 | 0.050 |
Why?
|
| Calcium | 1 | 1993 | 5756 | 0.050 |
Why?
|
| Presenilin-1 | 1 | 2023 | 635 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2012 | 63114 | 0.040 |
Why?
|
| Models, Psychological | 1 | 2003 | 811 | 0.040 |
Why?
|
| Patient Selection | 1 | 2011 | 4215 | 0.040 |
Why?
|
| South America | 1 | 2018 | 181 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2003 | 1850 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2005 | 6365 | 0.040 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2023 | 1121 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2023 | 1438 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 610 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 643 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2023 | 803 | 0.040 |
Why?
|
| Models, Biological | 1 | 1993 | 9583 | 0.040 |
Why?
|
| Visual Perception | 1 | 2005 | 1420 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 5686 | 0.040 |
Why?
|
| Mexico | 1 | 2018 | 690 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2003 | 1442 | 0.040 |
Why?
|
| Facial Paralysis | 1 | 2000 | 338 | 0.040 |
Why?
|
| Immunity | 1 | 2022 | 1012 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2023 | 1670 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2004 | 2250 | 0.030 |
Why?
|
| Australia | 1 | 2018 | 1170 | 0.030 |
Why?
|
| Nurses | 1 | 2005 | 2461 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2309 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2023 | 53288 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 1993 | 84 | 0.030 |
Why?
|
| Photolysis | 1 | 1993 | 92 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1993 | 114 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 2065 | 0.030 |
Why?
|
| Adolescent | 2 | 2016 | 85781 | 0.030 |
Why?
|
| Motivation | 1 | 2023 | 1971 | 0.030 |
Why?
|
| Biophysical Phenomena | 1 | 1993 | 327 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 15076 | 0.030 |
Why?
|
| Adult | 5 | 2016 | 214055 | 0.030 |
Why?
|
| Biophysics | 1 | 1993 | 383 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2008 | 5708 | 0.030 |
Why?
|
| Europe | 1 | 2018 | 3339 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2024 | 3589 | 0.030 |
Why?
|
| Diffusion | 1 | 1993 | 833 | 0.030 |
Why?
|
| Biological Clocks | 1 | 1993 | 321 | 0.020 |
Why?
|
| Hydroxycholesterols | 1 | 2010 | 25 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2023 | 3444 | 0.020 |
Why?
|
| Cytosol | 1 | 1993 | 901 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 29063 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2023 | 8324 | 0.020 |
Why?
|
| Calcium Channels | 1 | 1993 | 622 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 1993 | 957 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 1198 | 0.020 |
Why?
|
| Gene Expression | 1 | 2022 | 7799 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 40561 | 0.020 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 1993 | 871 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 7913 | 0.020 |
Why?
|
| Research Design | 1 | 2024 | 5987 | 0.020 |
Why?
|
| Kinetics | 1 | 1993 | 6473 | 0.020 |
Why?
|
| Mass Screening | 1 | 2021 | 5255 | 0.020 |
Why?
|
| Incidence | 1 | 2023 | 20947 | 0.020 |
Why?
|
| Risk Factors | 2 | 2017 | 72290 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 1151 | 0.010 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 979 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2018 | 7729 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2000 | 365 | 0.010 |
Why?
|
| Mutation | 1 | 2023 | 29786 | 0.010 |
Why?
|
| Granulocytes | 1 | 2000 | 548 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 3327 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2373 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2004 | 77449 | 0.010 |
Why?
|
| Prevalence | 1 | 2012 | 15226 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2000 | 1465 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2016 | 15295 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 6171 | 0.010 |
Why?
|
| United States | 1 | 2018 | 69872 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 15540 | 0.010 |
Why?
|
| Animals | 1 | 1993 | 168757 | 0.000 |
Why?
|